Medpace's strong performance leads to a 57% surge in stock price.

On Tuesday morning Eastern Time, the stock price of Medpace Holdings surged by 57%, as the company's second quarter financial report released earlier showed strong performance exceeding expectations. The clinical research organization raised its revenue guidance for 2025 to $2.42-2.52 billion, far exceeding the market's consensus of $2.18 billion. Medpace also raised its full-year GAAP earnings per share guidance, reflecting strong performance in new business orders and the positive impact of large-scale stock repurchases.